AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Hutchmed (China) Limited

Net Asset Value Jun 3, 2014

10503_dirs_2014-06-03_969d26d4-e14b-480b-920c-72f385b46eb7.html

Net Asset Value

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 7448I

Hutchison China Meditech Limited

03 June 2014

Hutchison China MediTech Limited ("Chi-Med")

(AIM: HCM)

Exercise of Options

London: Tuesday, 3 June 2014: Chi-Med announces that it has issued 768,182 ordinary shares of US$1.00 each (the "Shares") following the exercise of options by Mr Christian Hogg, Executive Director and Chief Executive Officer of Chi-Med, at an exercise price of GBP1.09 per share on 3 June 2014.  The options, granted in June 2005, will lapse after ten years.

Following the issue of the Shares, which are expected to be held as a long term investment by Mr Hogg, Mr Hogg is beneficially interested in 1,088,182 Shares, representing 2.06% of the current issued share capital of Chi-Med.

Ends

Enquiries

Chi-Med

    Christian Hogg, CEO
Telephone:      +852 2121 8200
Panmure Gordon (UK) Limited

    Richard Gray

    Andrew Potts
Telephone:      +44 20 7886 2500
Citigate Dewe Rogerson

    Anthony Carlisle

    David Dible
Telephone:      +44 20 7638 9571

Mobile:             +44 7973 611 888

Mobile:             +44 7967 566 919

About Chi-Med

Chi-Med is a China-based healthcare group focused on researching, developing, manufacturing and selling pharmaceuticals and health-related consumer products.  Its China Healthcare Division manufactures, markets and distributes prescription and over-the-counter pharmaceuticals in China.  Its Drug R&D Division focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases.  Its emerging Consumer Products Division focuses on organic and natural consumer products in Asia.

Chi-Med (LSE:HCM) is majority owned by the multinational conglomerate Hutchison Whampoa Limited (SEHK:13).  For more information, please visit: www.chi-med.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

RDSEALKDEADLEFF

Talk to a Data Expert

Have a question? We'll get back to you promptly.